The $195 Million Voucher: How Denali Turned a Hunter Syndrome Approval Into a Pipeline War Chest
Denali's $195M PRV sale after AVLAYAH's March 2026 FDA approval reveals how rare disease wins now fund the next...
biotech strategy
Biotech’s Uncomfortable Adolescence: Capital Is Back, But the Industry Has Changed Permanently
Biotech VC hit $26B in 2024 as IPOs lagged and China licensing surged—here's what the recovery's structure reveals about...
AI Rewires Biopharma BD — From Data Grunt to Strategic Lever
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...